DPN-205-734

DPN-205-734 is an orally administered cGMP-PDE inhibitor. DPN-205-734 exhibits positive inotropic effects in various animal cardiomyocytes. DPN-205-734 reduces blood pressure and total peripheral resistance in multiple animal models, demonstrating a debulking effect. DPN-205-734 can be used in research on cardiovascular and cerebrovascular diseases such as heart failure[1].

88594-78-9

12352005

H302-H315-H319-H335

Phosphodiesterase (PDE)

Metabolic Enzyme/Protease

Cardiovascular Disease

N#CC1=CC(C2=CC=C(C#N)C=C2)=C(C)NC1=O

C14H9N3O

235.24

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

[1]Salzmann R, et al. Pharmacological actions of DPN 205-734, a novel cardiotonic agent. J Cardiovasc Pharmacol. 1988 Oct;12 (4) :451-60.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-19089/

Reference compound2

No Development Reported